Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
BörsenkürzelETON
Name des UnternehmensEton Pharmaceuticals Inc
IPO-datumNov 09, 2018
CEOMr. Sean E. Brynjelsen
Anzahl der mitarbeiter31
WertpapierartOrdinary Share
GeschäftsjahresendeNov 09
Addresse21925 W Field Pkwy Ste 235
StadtDEER PARK
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl60010-7278
Telefon18477877361
Websitehttps://etonpharma.com/
BörsenkürzelETON
IPO-datumNov 09, 2018
CEOMr. Sean E. Brynjelsen
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten